Physician profile
Mikhail Charny
NPI 1659432805
$5,526.63
in general payments reported to CMS, 2019-2025
20 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $273 · 2021: $494 · 2022: $1,214 · 2023: $957 · 2024: $150 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,347.32 | 2022-2025 | Ubrelvy, Qulipta |
| Eisai INC. | $1,037.01 | 2019-2022 | |
| Amgen INC. | $725.32 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $358.31 | 2019-2022 | |
| Alkermes, INC. | $255.99 | 2025 | Lybalvi |
| Pfizer INC. | $232.31 | 2021-2025 | |
| Lilly USA, LLC | $226.40 | 2019-2023 | Mounjaro |
| Sk Life Science, INC. | $220.96 | 2022-2023 | Xcopri |
| Acorda Therapeutics, INC | $141.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $136.67 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Biogen, INC. | $125.00 | 2021 | |
| Ucb, INC. | $125.00 | 2019 | |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Axsome Therapeutics, INC. | $121.25 | 2023 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $85.85 | 2022 | |
| Neurocrine Biosciences, INC. | $77.15 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $23.35 | 2021 | |
| Acadia Pharmaceuticals INC | $18.58 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Charny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.